Antengene Announces XPOVIO® plus Bortezomib and Dexamethasone Included for Reimbursement by the PBS in Australia for the Treatment of Relapsed and/or Refractory Multiple Myeloma
- XPOVIO® (selinexor) is the first and only selective inhibitor of nuclear export (SINE) inhibitor approved by the Therapeutic Goods Administration (TGA) of Australia for patients with relapsed and/or refractory multiple myeloma (R/R MM) and in triple class refractory R/R MM. - This inclusion by the Pharmaceutical Benefits Scheme (PBS) for the...
CBC GROUP RELEASES 2022 ESG REPORT
Guided by the firm's commitment to drive positive and meaningful impact while delivering better healthcare for all SINGAPORE, June 1, 2023 /PRNewswire/ -- CBC Group ("CBC"), Asia's largest healthcare-dedicated investment firm, today published its Environmental, Social and Governance ("ESG") report for 2022. This year's report, titled "Creating Value Through ESG Integration", reflects CBC's commitment towards value generation by integrating...
Xinhua Silk Road: Chinese Lingzhi brand Longevity Valley promotes inheritance of a century-old national treasure to Brunei foreign envoys
BEIJING, June 1, 2023 /PRNewswire/ -- A delegation of the renowned Chinese Lingzhi brand, Zhejiang Longevity Valley Botanical Co., Ltd, recently visited the Embassy of Brunei Darussalam in China to showcase Chinese traditional culture and wisdom of health philosophy embedded in the brand to Brunei. Photo shows Li Zhenyu, the General Manager of Zhejiang...
Mediso installs 100% cryogen-free 7T MRI at the University of Milano-Bicocca, Italy
BUDAPEST, Hungary, June 1, 2023 /PRNewswire/ -- Mediso Medical Imaging Systems recently installed a state-of-the-art 7T MRI at the University of Milano-Bicocca. The nanoScan® MRI 7T installed is equipped with a state-of-the-art cryogen-free superconducting magnet. Uniquely on the preclinical market, the pulse tube cryocooler is mounted at the back of the scanner...
National Comprehensive Cancer Network Joins Collaboration to Improve Standards in Cancer Care for Vietnam
United States-based NCCN representatives visit Hanoi, Vietnam to work with local experts to improve quality-of-life for patients with cancer throughout the country. PHILADELPHIA and HANOI, Vietnam, June 1, 2023 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—a not-for-profit alliance of leading cancer centers in the United States—today announced the signing of a...
Brii Biosciences Announces First Subject Dosed in Phase 1 Clinical Trial of BRII-297, Long-Acting Injectable for the Treatment of Anxiety and Depressive Disorders
BRII-297, a first-of-its-kind treatment option for anxiety and depressive disorders, has the potential to enable greater therapeutic adherence and convenience for patients DURHAM, N.C. and BEIJING, June 1, 2023 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and...
Argon Strengthens Biopsy Portfolio with SuperCore Advantage™ Instrument
PLANO, Texas, June 1, 2023 /PRNewswire/ -- Argon Medical Devices, a leading provider of device solutions for Interventional Radiology, Vascular Surgery, Interventional Cardiology, and Oncology, announced the launch of the SuperCore Advantage™ Semi-Automatic Biopsy Instrument as the newest addition to its soft tissue biopsy product portfolio in the United States. The SuperCore...
Advances of Qilu Pharmaceutical’s QL1706 in Clinical Research Presented at ASCO Annual Meeting
JINAN, China, June 1, 2023 /PRNewswire/ -- The American Society of Clinical Oncology (ASCO) recently announced the selected abstracts for the prestigious ASCO 2023 Annual Meeting. Four clinical research abstracts on QL1706 (iparomlimab/tuvonralimab), an innovative bifunctional antibody for immunotherapy, were accepted in the Poster Session. Two of the posters focus on the latest clinical...
Vazyme Signs Global Strategic Cooperation Agreement with Azenta
NANJING, China, May 31, 2023 /PRNewswire/ -- Vazyme (688105.SH), China's leading biotechnology company, has officially signed a global strategic cooperation agreement with Azenta Life Sciences ("Azenta", Nasdaq: AZTA), which will promote to establish "one-stop" service process for both companies in the fields of next-generation sequencing, automated library preparation, raw material supply, experimental consumables, sample storage and more. ...
Actinogen to present progress on Cognitive Impairment in Depression and Alzheimer’s Disease Phase 2 trials at the BIO International Convention
Xanamem® is an oral, brain-penetrant tissue cortisol synthesis inhibitor that has shown promising safety and clinical activity in three placebo-controlled trials and has the potential to treat a variety of neurodegenerative and neuropsychiatric diseases SYDNEY, May 31, 2023 /PRNewswire/ -- Actinogen Medical Limited (ASX: ACW) CEO Dr Steven Gourlay and CMO Dr...
